



A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors; Protocol Number: LOXO-RET-18036 (J2G-OX-JZJJ)

Status: Recruiting

Eligibility Criteria

Conditions & Interventions

More Information

Description: This is an open-label, multi-center, Phase 1/2 study of oral LOXO-292 in pediatric patients with an activating RET alteration and an advanced solid or

primary CNS tumor.

Contact(s): Allison Fullenkamp - fulle631@umn.edu

Principal Investigator: Emily Greengard

IRB

Number: STUDY00008874

System ID: 26714

Thank you for choosing StudyFinder. Please visit http://studyfinderstaging.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.